Corvus Pharmaceuticals, Inc. Contracts & Agreements

Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on May 7, 2024)

Employment Agreement, dated as of February 2, 2024 by and between Corvus Pharmaceuticals, Inc. and Jeffrey S. Arcara (Filed With SEC on May 7, 2024)

Form of Pre-Funded Warrant (Filed With SEC on May 6, 2024)

Form of Common Warrant (Filed With SEC on May 6, 2024)

Securities Purchase Agreement, dated May 1, 2024, between the Company and the Investors (Filed With SEC on May 6, 2024)

Amendment No. 1 to Sales Agreement, dated as of May 1, 2024, between Corvus Pharmaceutical, Inc. and Jefferies LLC (Filed With SEC on May 1, 2024)

Amendment to Amended and Restated Employment Agreement, dated as of March 31, 2023, by and between Corvus Pharmaceuticals, Inc. and Richard A. Miller (Filed With SEC on August 8, 2023)

Open Market Sale Agreement, dated November 1, 2021, by and between Corvus Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on March 10, 2022)

Sales Agreement, dated as of November 1, 2021, between Corvus Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on November 2, 2021)

Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 25, 2021)

Underwriting Agreement, dated as of February 12, 2021, among Corvus Pharmaceuticals, Inc. and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC as the underwriters (Filed With SEC on February 17, 2021)

Phase I/IB Combination Study Agreement, dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on October 29, 2020)

Framework Agreement, dated October 5, 2020, by and among Corvus Hong Kong Limited, Angel Pharmaceutical Co., Ltd., Jiaxng Puissance Angel Equity Investment Partnership (Limited... (Filed With SEC on October 5, 2020)

Transition and Consulting Agreement, dated June 30, 2020 by and between Corvus Pharmaceuticals, Inc. and Joseph Buggy (Filed With SEC on July 30, 2020)

Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2020)

Amendment No. 1 to the Phase I/IB Combination Study Agreement, dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)

Amendment No. 2 to the Phase I/IB Combination Study Agreement, dated August 1, 2019, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)

Amendment No. 1 to the Phase 1b/II Combination Study Agreement dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)

Exclusive License Agreement dated April 21, 2017, by and between Corvus Pharmaceuticals, Inc. and Monash University (Filed With SEC on March 9, 2020)

Form of Warrant (Filed With SEC on November 12, 2019)

Exchange Agreement, dated November 8, 2019, by and among, Corvus Pharmaceuticals, Inc., Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value... (Filed With SEC on November 12, 2019)

Seventh Amendment to Office Lease, dated as of October 11, 2018, by and between Corvus Pharmaceuticals, Inc. and ARE819/863 Mitten Road, LLC (Filed With SEC on March 7, 2019)

Offer Letter, dated as of January 7, 2019 by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher (Filed With SEC on March 7, 2019)

Change in Control and Severance Agreement, dated January 28, 2019, by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher (Filed With SEC on March 7, 2019)

Sixth Amendment to Office Lease dated as of April 5, 2018, by and between , Corvus Pharmaeuticals, Inc. and ARE-819/863 Mitten Road, LLC (Filed With SEC on August 2, 2018)

Employment Agreement, dated November 26, 2014, by and between the Company and Joseph J. Buggy (Filed With SEC on May 3, 2018)

Fifth Amendment to Office Lease dated as of March 2, 2018, by and between , Corvus Pharmaeuticals, Inc. and ARE-819/863 Mitten Road, LLC (Filed With SEC on May 3, 2018)

Underwriting Agreement, dated as of March 8, 2018, among Corvus Pharmaceuticals, Inc. and Credit Suisse Securities (USA) LLC and Jefferies LLC, as representatives of the... (Filed With SEC on March 21, 2018)

Offer Letter, dated as of November 22, 2017 by and between Corvus Pharmaceuticals, Inc. and Daniel Hunt (Filed With SEC on March 1, 2018)

Change in Control and Severance Agreement dated December 13, 2017, by and between Corvus Pharmaceuticals, Inc. and Daniel Hunt (Filed With SEC on March 1, 2018)

Sales Agreement, dated as of September 20, 2017, between Corvus Pharmaceuticals, Inc. and Cowen and Company, LLC (Filed With SEC on September 20, 2017)

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with... (Filed With SEC on August 3, 2017)

FOURTH AMENDMENT TO LEASE (Filed With SEC on November 3, 2016)

THIRD AMENDMENT TO LEASE (Filed With SEC on August 4, 2016)

CORVUS PHARMACEUTICALS, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on August 4, 2016)

LICENSE AGREEMENT Dated February 25, 2015 (1) Vernalis (R&D) Limited (2) Corvus Pharmaceuticals, Inc. (Filed With SEC on March 10, 2016)

Corvus Pharmaceuticals, Inc. UNDERWRITING AGREEMENT (Filed With SEC on February 8, 2016)

CORVUS PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on February 8, 2016)

CORVUS PHARMACEUTICALS, INC. 2016 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE (Filed With SEC on February 8, 2016)

LICENSE AGREEMENT Dated February 25, 2015 (1) Vernalis (R&D) Limited (2) Corvus Pharmaceuticals, Inc. (Filed With SEC on February 8, 2016)

PHASE I/IB COMBINATION STUDY AGREEMENT BY AND BETWEEN GENENTECH, INC. AND CORVUS PHARMACEUTICALS, INC. (Filed With SEC on February 8, 2016)

Category

Industry

Companies

Contracts

Corvus Pharmaceuticals, Inc. Contracts & Agreements